Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(30 sites)

United States

Pulmonary Associates, PA, Mesa, Arizona

Dignity Health Norton Thoracic Institute, Phoenix, Arizona

The University of California San Francisco, San Francisco, California

Loyola University Medical Center (LUMC), Maywood, Illinois

University of Kansas Medical Center Research Institute, Inc, Kansas City, Kansas

Tufts Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Michigan Health System, Michigan Center, Michigan

The Lung Research Center, LLC, Chesterfield, Missouri

Duke University Medical Center, Durham, North Carolina

Pulmonix Research, LLC, Greensboro, North Carolina

Legacy Research Institute, Portland, Oregon

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

The U.S. Department of Veterans Affairs, Charleston, South Carolina

Lowcountry Lung and Critical Care, Charleston, South Carolina

Baylor Scott & White Research Institute, Dallas, Texas

The University of Texas Southwestern Medical Center, Dallas, Texas

Baylor College of Medicine, Houston, Texas

The University of Texas Health San Antonio Medical Arts & Research Center, San Antonio, Texas

South Korea

Inje University Busan Paik Hospital, Busan, Busan

The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do

Myongji Hospital, Goyang-si, Gyeonggi-do

Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Gyeonggido

Ajou University Hospital, Hwaseong-si, Gyeonggido

Seoul National University Hospital, Seoul, Seoul

Severance Hospital, Yonsei University Health System, Seoul, Seoul

Asan Medical Center, Seoul, Seoul

Samsung Medical Center, Seoul, Seoul

Ulsan University Hospital, Ulsan, Ulsan